You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《異動股》復星醫藥(02196.HK)倒跌6% 曾考驗10天線
阿思達克 07-28 10:49
美國政府上周斥19.5億美元購買輝瑞與德國生物科技公司BioNTech研發1億劑新冠肺炎疫苗。由於BioNTech是復星醫藥(02196.HK)戰略合作夥伴,消息刺激後者股價近日反覆探頂,昨天曾升至39.5元,受制上周五盤中所創近兩年高位40.15元,今天股價高開升至39元無以為繼,掉頭考驗10天線(35.16元)支持,最低見35.1元,現造35.9元,倒跌5.9%,成交1,135萬股,涉資4.15億元。

復星醫藥(600196.SH)昨天收市後,就A股於上周四至本周一連續三個交易日收市價升幅均偏離累計超過20%發聲明指,集團不存在披露而未披露的重大信息。至於公司控股子公司上海復生醫藥產業發展BioNTech許可的用於預防新冠肺炎的mRNA疫苗雖然已獲中國國家藥品監督管理局批准於內地開展臨床試驗,但由於該疫苗還尚處於I期臨床試驗啟動階段,根據目前內地關於疫苗產品的審批要求及研發經驗,該疫苗尚需完成臨床I期、II期及III期試驗,上市批准及生產設施認證/核查(如適用)等主要環節且受到諸多不確定因素影響。因此,該疫苗在內地能否獲得相關藥品監管機構上市批准及上市批准時間等方面存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account